What is the recommended approach to evaluate and treat hypothyroidism, including initial thyroid‑stimulating hormone and free thyroxine testing, levothyroxine dosing and titration, monitoring schedule, and management of subclinical disease and pregnancy?

Approach to Hypothyroidism

Initial Diagnostic Evaluation

Measure serum TSH as the first-line test for suspected hypothyroidism, as it demonstrates approximately 98% sensitivity and 92% specificity for detecting thyroid dysfunction. 1, 2

• If TSH is elevated, measure free T4 to distinguish between subclinical hypothyroidism (normal free T4) and overt hypothyroidism (low free T4) 1, 3
• Confirm any abnormal TSH with repeat testing after 3–6 weeks, since 30–60% of elevated TSH values normalize spontaneously 1, 4
• Measure anti-TPO antibodies to identify autoimmune etiology (Hashimoto's thyroiditis), which predicts higher progression risk: 4.3% per year versus 2.6% in antibody-negative individuals 1, 4

Common pitfall: Do not treat based on a single elevated TSH value—transient elevations from acute illness, medications, or recovery from thyroiditis are common 1

---

Treatment Initiation Based on TSH Level

TSH >10 mIU/L with Normal Free T4 (Severe Subclinical Hypothyroidism)

Initiate levothyroxine therapy immediately regardless of symptoms, as this threshold carries approximately 5% annual risk of progression to overt hypothyroidism and is associated with cardiac dysfunction and adverse lipid profiles. 1, 5

• Evidence quality is rated as "fair" by expert panels 1
• Treatment may improve symptoms and lower LDL cholesterol 1, 5

TSH 4.5–10 mIU/L with Normal Free T4 (Mild Subclinical Hypothyroidism)

Routine levothyroxine treatment is NOT recommended for asymptomatic patients, as randomized controlled trials show no symptomatic benefit. 1

Consider treatment in specific situations:

• Symptomatic patients (fatigue, weight gain, cold intolerance, constipation) may benefit from a 3–4 month trial with clear evaluation of response 1
• Pregnant women or those planning pregnancy—target TSH <2.5 mIU/L in first trimester 1, 6
• Patients with positive anti-TPO antibodies (higher progression risk) 1, 4
• Patients with goiter or infertility 1, 5

Monitor without treatment: Recheck TSH and free T4 every 6–12 months 1

Overt Hypothyroidism (Elevated TSH + Low Free T4)

Start levothyroxine immediately to prevent cardiovascular dysfunction, adverse lipid profiles, and quality of life deterioration. 1, 3

---

Levothyroxine Dosing Strategy

Initial Dosing

For patients <70 years without cardiac disease: Start with full replacement dose of approximately 1.6 mcg/kg/day 1, 7

For patients >70 years OR with cardiac disease/multiple comorbidities: Start with a lower dose of 25–50 mcg/day to avoid precipitating myocardial infarction, heart failure, or arrhythmias 1, 4, 7, 5

Critical safety consideration: Before initiating levothyroxine, rule out concurrent adrenal insufficiency by measuring morning cortisol and ACTH—starting thyroid hormone before corticosteroids can precipitate life-threatening adrenal crisis 1, 5

Dose Titration

• Increase dose by 12.5–25 mcg increments every 6–8 weeks based on TSH response 1, 7
• Use smaller increments (12.5 mcg) for elderly patients or those with cardiac disease 1, 4
• Target TSH within reference range: 0.5–4.5 mIU/L with normal free T4 1, 4, 7

---

Monitoring Schedule

During Dose Titration

Recheck TSH and free T4 every 6–8 weeks after any dose adjustment until target TSH is achieved. 1, 4, 7

• Free T4 helps interpret ongoing abnormal TSH levels during therapy, as TSH may take longer to normalize 1

After Stabilization

Once on stable dose with target TSH (0.5–4.5 mIU/L), repeat TSH every 6–12 months or sooner if symptoms change. 1, 4, 7

---

Management of Overtreatment (Iatrogenic Hyperthyroidism)

Approximately 25% of patients on levothyroxine are unintentionally maintained on doses sufficient to fully suppress TSH, increasing serious complication risks. 1

Dose Reduction Protocol

• TSH <0.1 mIU/L: Decrease levothyroxine by 25–50 mcg immediately 1, 7
• TSH 0.1–0.45 mIU/L: Decrease by 12.5–25 mcg, particularly in elderly or cardiac patients 1, 4

Risks of Prolonged TSH Suppression

• Atrial fibrillation (3–5 fold increased risk, especially in patients ≥60 years) 1, 4
• Osteoporosis and fractures, particularly in postmenopausal women 1, 4
• Increased cardiovascular mortality 1

Common pitfall: Failing to distinguish between patients who require TSH suppression (thyroid cancer) versus those who don't (primary hypothyroidism) 1

---

Special Populations

Pregnancy

For women with pre-existing hypothyroidism: Increase levothyroxine dose by 25–50% immediately upon pregnancy confirmation 1

• Monitor TSH every 4 weeks until stable, then at minimum once per trimester 1, 7
• Target TSH <2.5 mIU/L in first trimester 1, 6
• Levothyroxine requirements typically increase 25–50% during pregnancy 1
• Reduce to pre-pregnancy dose immediately after delivery and recheck TSH 4–8 weeks postpartum 7

For new-onset hypothyroidism in pregnancy:

• TSH ≥10 mIU/L: Start 1.6 mcg/kg/day 7
• TSH <10 mIU/L: Start 1.0 mcg/kg/day 7

Elderly Patients (>70 years)

Start at 25–50 mcg/day and titrate slowly by 12.5 mcg increments every 6–8 weeks. 1, 4, 7

• Slightly higher TSH targets (up to 5–6 mIU/L) may be acceptable in very elderly patients to avoid overtreatment risks 4
• Approximately 12% of persons aged ≥80 years have TSH >4.5 mIU/L without underlying thyroid disease 1

Patients on Immune Checkpoint Inhibitors

• Thyroid dysfunction occurs in 6–9% with anti-PD-1/PD-L1 therapy and 16–20% with combination immunotherapy 1
• Consider treatment even for subclinical hypothyroidism if fatigue or other symptoms are present 1
• Continue immunotherapy in most cases—thyroid dysfunction rarely requires treatment interruption 1

---

Critical Pitfalls to Avoid

1. Never start thyroid hormone before ruling out adrenal insufficiency in suspected central hypothyroidism—this can precipitate adrenal crisis 1, 5

2. Do not treat based on single elevated TSH—confirm with repeat testing as 30–60% normalize spontaneously 1, 4

3. Avoid excessive dose increases—overtreatment occurs in 14–21% of treated patients and increases risk for atrial fibrillation, osteoporosis, and cardiac complications 1

4. Do not adjust doses too frequently—wait 6–8 weeks between adjustments to reach steady state 1, 7

5. Recognize transient causes of TSH elevation: acute illness, recent iodine exposure (CT contrast), recovery from thyroiditis, or medications (lithium, amiodarone, interferon) 1, 8